The experimental medicine ziltivekimab didn't translate into a statistically meaningful reduction in major cardiovascular adverse events, Novo said Friday.
Source: [CNBC](https://www.cnbc.com/2026/07/31/novo-nordisk-trial-results.html)
📰 Read Full Story
This is an aggregated headline summary. For the complete report, visit the original publisher.
Continue Reading at CNBC ↗